Program cell death‐1 (PD‐1) blockade treatment has been shown effective in cases with relapsed/refractory classical Hodgkin Lymphoma (R/R cHL), while prognostic biomarkers remain unclear. This evidence concerns the gene PDCD1 and classic Hodgkin lymphoma.